Iprabronch (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic (M1 and M3) receptors in the airway, preventing acetylcholine‑mediated contraction of bronchial smooth muscle and secretion from submucosal glands. This inhibition reduces bronchoconstriction and mucus production, leading to widened airways and easier breathing. Its low systemic absorption keeps the effect largely localized to the lungs.

The prescribed dose of Iprabronch is determined by the treating physician based on the patient’s condition, severity, and response to therapy. Dosage may vary between maintenance regimens and acute symptom relief, and the prescriber will provide specific instructions on frequency, inhalation technique, and duration of treatment.

Safety data for ipratropium bromide in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in milk.

To request Iprabronch, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Iprabronch (ipratropium bromide) belongs to the anticholinergic class, whereas many alternatives such as albuterol are β2‑agonists. Anticholinergics provide bronchodilation by blocking muscarinic receptors, offering a complementary mechanism to β2‑agonists. Combination therapy can improve symptom control in COPD and asthma, especially when a single class does not achieve optimal relief.

Iprabronch should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the container tightly closed when not in use and avoid freezing. Follow any additional handling instructions provided by the supplier to maintain product integrity.

Iprabronch is supplied as an inhalation solution intended for use with a nebulizer or appropriate inhalation device. The patient inhales the medication through the mouth, following the device’s instructions for dosage and technique. Proper inhalation ensures the drug reaches the lower airways where it exerts its bronchodilatory effect.

Serious adverse reactions, though rare, include paradoxical bronchospasm, severe allergic responses such as angioedema or anaphylaxis, and significant urinary retention in susceptible individuals. Patients should be instructed to seek immediate medical attention if they experience worsening breathing, swelling of the face or throat, or inability to urinate.

Iprabronch is contraindicated in patients with known hypersensitivity to ipratropium bromide or any component of the formulation. Caution is also advised for individuals with narrow‑angle glaucoma, severe urinary retention, or significant renal impairment, where alternative therapies may be more appropriate.